A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 889
- Registration Number
- NCT01576718
- Locations
- 🇭🇷
Teva Investigational Site 85502, Zagreb, Croatia
🇬🇷Teva Investigational Site 85533, Athens, Greece
🇬🇷Teva Investigational Site 85532, Larissa, Greece
Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol
- Conditions
- Allergic Rhinitis
- Interventions
- Drug: BDP HFA Nasal AerosolDrug: BDP HFA Inhalation Aerosol (QVAR)
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01537692
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 511
- Registration Number
- NCT01508936
- Locations
- 🇺🇸
Investigational Site 865, Miami, Florida, United States
🇺🇸Investigational Site 881, Miami, Florida, United States
🇺🇸Investigational Site 809, Tucson, Arizona, United States
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 909
- Registration Number
- NCT01479621
- Locations
- 🇺🇸
Teva Investigational Site 10173, Bakersfield, California, United States
🇺🇸Teva Investigational Site 10183, Philadelphia, Pennsylvania, United States
🇺🇸Teva Investigational Site 10144, Columbus, Ohio, United States
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT01424813
- Locations
- 🇺🇸
Teva Investigational Site 10066, San Diego, California, United States
🇺🇸Teva Investigational Site 10077, Birmingham, Alabama, United States
🇺🇸Teva Investigational Site 10079, Phoenix, Arizona, United States
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT01404117
A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women
- Conditions
- HemostasisOral Contraceptive
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 293
- Registration Number
- NCT01388491
- Locations
- 🇮🇹
Teva Investigational Site 30012, Catania, Italy
🇮🇱Teva Investigational Site 80017, Modi'in, Israel
🇮🇹Teva Investigational Site 30016, Siena, Italy
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01348919
- Locations
- 🇺🇸
Teva Investigational Site 1, Augusta, Georgia, United States
🇳🇿Teva Investigational Site 204, Auckland, New Zealand
🇺🇸Teva Investigational Site 2, Houston, Texas, United States
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT01311713
- Locations
- 🇺🇸
Teva Investigational Site 4, Saint Louis, Missouri, United States
🇺🇸Teva Investigational Site 1, Aurora, Colorado, United States
🇺🇸Teva Investigational Site 2, Philadelphia, Pennsylvania, United States
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
- Conditions
- Seasonal Allergic RhinitisSAR
- Interventions
- Drug: BDP HFADrug: Placebo nasal aerosol
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 715
- Registration Number
- NCT01307319
- Locations
- 🇺🇸
Teva Clinical Study Site, Richmond, Virginia, United States